NCT03724136 - Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

October 24, 2018

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions

Alzheimer DiseaseAlzheimer DementiaVascular DementiaLewy Body DiseaseLewy Body Dementia With Behavioral Disturbance (Disorder)Dementia, MixedParkinson-Dementia SyndromeChronic Traumatic EncephalopathyHuntington's DementiaWernicke Korsakoff SyndromeTraumatic Brain InjuryDementia, Multi-InfarctAutismAutism Spectrum DisorderAutistic BehaviorAutistic Disorder, Current or Active StateCadasilLATE Limbic-predominant Age-related TDP-43 Encephalopathy

Interventions

PROCEDURE

Intravenous Bone Marrow Stem Cell (BMSC) Fraction

14 cc of BMSC fraction separated from bone marrow aspirate and filtered with 150 micron filter and administered intravenously.

PROCEDURE

Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction

Approximately 1 cc of BMSC fraction separated from bone marrow aspirate and administered to the nasal mucosa topically.

PROCEDURE

Near Infrared Light

Near Infrared Light will be administered using an FDA cleared medical device on the preoperative day and the first postoperative day as tolerated to the general area of the frontal bone.

Trial Locations (3)

33065

MD Stem Cells, Coral Springs

06880

MD Stem Cells, Westport

Unknown

Medcare Orthopaedics & Spine Hospital, Dubai